Literature DB >> 772771

Laboratory trials with inactivated vaccines against Escherichia coli (O78 K80) infection in fowls.

J R Deb, E G Harry.   

Abstract

Laboratory trials made with five inactivated (O78 K80) Escherichia coli vaccines showed that the greatest degree of protection against an intramuscular challenge with the homologous strain was obtained with an alum precipitated vaccine. This vaccine was equally effective when administered by the subcutaneous, intramuscular or intraperitoneal route. Maximal protection, persisting for at least six weeks, was obtained by inoculating chicks at three weeks of age with a dose of approximately 1-5 X 10(9) cells in 0.5 ml. Some degree of protection was obtained, however, in chicks vaccinated earlier. There was no evidence that this vaccine provided any cross protection against other pathogenic serotypes of E coli. No adverse effect was noted on growth rate or carcase quality in the chicks vaccinated. Immunological studies showed that protection was not related to the production of O and K serum agglutinins.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 772771

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  6 in total

1.  Outer membrane protein patterns mark clones of Escherichia coli O2 and O78 strains that cause avian septicemia.

Authors:  V Kapur; D G White; R A Wilson; T S Whittam
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

2.  Passive immunization with antibodies against iron-regulated outer membrane proteins protects turkeys from Escherichia coli septicemia.

Authors:  C A Bolin; A E Jensen
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

3.  Characterization of Escherichia coli isolated from cases of avian colibacillosis.

Authors:  B J Allan; J V van den Hurk; A A Potter
Journal:  Can J Vet Res       Date:  1993-07       Impact factor: 1.310

4.  A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys.

Authors:  J K Kwaga; B J Allan; J V van der Hurk; H Seida; A A Potter
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

5.  Immune responses associated with homologous protection conferred by commercial vaccines for control of avian pathogenic Escherichia coli in turkeys.

Authors:  Jean-Rémy Sadeyen; Zhiguang Wu; Holly Davies; Pauline M van Diemen; Anita Milicic; Roberto M La Ragione; Pete Kaiser; Mark P Stevens; Francis Dziva
Journal:  Vet Res       Date:  2015-01-23       Impact factor: 3.683

6.  Assessment of immunity against avian colibacillosis induced by an aroA mutant containing increased serum survival gene in broilers.

Authors:  Taghi Zahraei Salehi; Saeid Tabatabaei; Vahid Karimi; Bahar Nayeri Fasaei; Abdullah Derakhshandeh; Ali Omid Nekoui Jahromi
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.